<DOC>
	<DOC>NCT01614691</DOC>
	<brief_summary>This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis</brief_summary>
	<brief_title>Safety and Efficacy of SPARC1203 in Allergic Rhinitis</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Male and female patients aged 18 to 65 years (both inclusive) with history of seasonal allergic rhinitis and positive skin prick test History or presence of perennial allergic rhinitis Upper or lower respiratory tract infection 2 weeks before Visit 2 Significant pulmonary disease other than allergic rhinitis or mild asthma controlled by beta2agonists alone Immunizations or vaccinations within 4 weeks prior to Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>